[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,773
  • Shares Outstanding, K 72,484
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,800 K
  • EBIT $ -58 M
  • EBITDA $ -57 M
  • 60-Month Beta -0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.31

Options Overview Details

View History
  • Implied Volatility 172.04% (+48.51%)
  • Historical Volatility 59.50%
  • IV Percentile 52%
  • IV Rank 10.60%
  • IV High 791.65% on 11/20/25
  • IV Low 98.55% on 01/21/26
  • Expected Move (DTE 16) 0.3740 (20.78%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,845
  • Volume Avg (30-Day) 1,365
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 64,517
  • Open Int (30-Day) 55,299
  • Expected Range 1.4260 to 2.1740

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.21
  • Number of Estimates 4
  • High Estimate $-0.17
  • Low Estimate $-0.31
  • Prior Year $-0.27
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1250 +60.00%
on 08/03/26
1.8700 -3.74%
on 09/01/26
+0.6300 (+53.85%)
since 07/31/26
3-Month
1.1000 +63.64%
on 06/09/26
1.8700 -3.74%
on 09/01/26
+0.4100 (+29.50%)
since 06/01/26
52-Week
0.8719 +106.45%
on 11/21/25
2.9900 -39.80%
on 10/06/25
-0.1500 (-7.69%)
since 08/29/25

Most Recent Stories

More News
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated...

BMEA : 1.8000 (+7.14%)
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

SAN CARLOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company,...

BMEA : 1.8000 (+7.14%)
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes ...

BMEA : 1.8000 (+7.14%)
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes

BMEA : 1.8000 (+7.14%)
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027 Enrollment also ongoing...

BMEA : 1.8000 (+7.14%)
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first...

BMEA : 1.8000 (+7.14%)
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including...

BMEA : 1.8000 (+7.14%)
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader...

BMEA : 1.8000 (+7.14%)
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle...

BMEA : 1.8000 (+7.14%)
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking...

BMEA : 1.8000 (+7.14%)

Business Summary

Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California.

See More

Key Turning Points

3rd Resistance Point 2.0888
2nd Resistance Point 1.9794
1st Resistance Point 1.8897
Last Price 1.8000
1st Support Level 1.6906
2nd Support Level 1.5812
3rd Support Level 1.4915

See More

52-Week High 2.9900
Fibonacci 61.8% 2.1809
Fibonacci 50% 1.9310
Last Price 1.8000
Fibonacci 38.2% 1.6810
52-Week Low 0.8719

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.